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Conversely, these participants had 3-doctor visits, one emergency
room visit and two hospitalizations. Ninety-eight percent of the
graduated participants reported being satisﬁed with the program.
CONCLUSIONS: Enrollment in the CarePatterns Heart Moni-
toring program successfully trains participants to monitor their
weight daily and develop an Action Plan. The monitoring
program also increases overall retention and participants report
strong satisfaction with the program. These factors all should
contribute to lower medical utilization and improved clinical
outcomes.
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Until the mid-1990s, Canadian consensus guidelines identiﬁed ß-
blocker therapy as being contraindicated for persons with heart
failure (HF). Based on placebo-controlled randomized trials and
economic evaluations that appeared subsequently, more recent
consensus statements reversed that recommendation and advo-
cated widespread use of ß-blockers for moderate to severe HF.
OBJECTIVES: Our goal was to estimate, among elderly persons
discharged after a ﬁrst HF hospitalization, the extent to which
ß-blocker use increased after the reversal in recommendations.
METHODS: We carried out a retrospective cohort study using
a linked administrative database of hospital separations and
medication claims. Included were all residents of British Colum-
bia, Canada (BC), aged 65 years and over, sent home after being
hospitalized with a principal discharge diagnosis of HF during
ﬁscal years 1990–2001. To eliminate prevalent hospitalizations,
we excluded subjects discharged with any diagnosis of HF
between 1990 and 1993. The proportion dispensed a ß-blocker
within 30 days of discharge was estimated for triennial periods
and was modeled using logistic regression. RESULTS: For all
subjects, the proportion dispensed a ß-blocker after their ﬁrst
hospitalization for HF increased from 2.2% in 1993–95 through
4.0% in 1996–98 to 7.4% in 1998–2001 (crude odds ratio =
3.6; 95% conﬁdence interval 3.3 to 3.9). CONCLUSIONS: In
this population-based study, we found that in the latter half of
the 1990s, there was a three-fold increase in the use of ß-blocker
therapy after an initial hospitalization for HF, consistent with
new guidelines. However, absolute rates of ß-blocker use
remained lower than 10% in BC, indicating that many patients
may yet be receiving the beneﬁt.
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OBJECTIVES: To examine patterns of use of drugs for the treat-
ment of chronic heart failure (CHF) and how these patterns
change over time. METHODS: We identiﬁed a national cohort
of patients with CHF in the Department of Veterans Affairs (VA)
beginning October 1, 1998 (FY99) and obtained their outpatient
pharmacy prescription ﬁll records for FY99 through FY02. We
tabulated the proportion of patients receiving ﬁlled prescriptions
for several categories of drugs across years. To adjust for sever-
ity of illness and distinguish birth cohort effects from real
changes in practice, patients were stratiﬁed based on number of
years in the cohort. We then compared patterns of use between
groups over time. RESULTS: The total number of patients
ranged from 222,288 in FY99 to 301,485 in FY02. The average
age(sd) ranged from 69.7(10.3) to 71.1(10.4). The most preva-
lent categories in FY99 were angiotensin-converting enzyme
(ACE) or angiotensin II inhibitors (65.6%), loop diuretics
(64.2%), digitalis glycosides (40.3%), calcium channel blockers
(CCB, 37.0%), beta blockers (37.1%) and statins (36.3%). By
FY02, digitalis and CCBs decreased to 34.0% and 32.4%, 
while beta blockers and statins increased to 54.0% and 51.8%,
respectively. ACE or angiotensin II inhibitor and loop diuretic
use remained relatively constant (69.3% and 62.3%, respec-
tively). Among newly diagnosed patients, 40.6% in FY99
received beta blockers; in FY02, 58.8% were started on beta
blockers. Of survivors from FY99, beta blocker use increased to
52.7% by FY02, indicating that 29.8% of surviving patients
were added to beta blockers and/or survived longer than patients
who were not started on that drug class. Similar patterns were
observed within other groups. CONCLUSIONS: Pharmacother-
apy patterns in the VA changed for patients with CHF from 1999
to 2002, as new evidence emerged from clinical trials. Future
work will link these changes in process of care to survival, 
utilization and cost.
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OBJECTIVE: Heart failure (HF) is a debilitating chronic condi-
tion characterized by steady deterioration that is punctuated
with acute episodes of decompensation requiring hospitalization.
It is among the most costly conditions, consuming between two
and 3% of health care budgets in western countries, 2/3 of which
is spent on hospitalizations. During the 1980s, increasing age-
speciﬁc hospitalization rates of HF were observed. However,
there is little Canadian information on trends in HF hospital-
izations during the 1990s, a period when efﬁcacious therapies
for HF, including angiotensin converting enzymes and ß-block-
ers, were being progressively incorporated into clinical practice.
METHODS: Using the hospital separations database, we
obtained abstracts of all residents of British Columbia, Canada
(BC), aged 40 years and over, having a principal discharge diag-
nosis of HF during ﬁscal years 1990–2001. To eliminate preva-
lent hospitalizations, we excluded subjects who were discharged
with any diagnosis of HF between 1990 and 1993. Age- and 
sex-speciﬁc, and directly age-standardized, rates of initial HF
hospitalization were estimated using population denominators.
Poisson regression was used to model changes over time.
RESULTS: For both women and men, age-standardized rates
decreased 37% from 1993 to 2001. Decreases of this magnitude
were observed over all ages. CONCLUSIONS: In this popula-
tion-based study, we found that declines in rates of initial 
hospitalization for HF occurred in BC at the same time that efﬁ-
cacious therapies were incorporated into practice. While this
ﬁnding is encouraging, alternative explanations such as concur-
rent hospital downsizing that restricted admission to more severe
cases, must be ruled out before concluding that persons with HF
were managed better.
